We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Amends GSK’s/Vir’s Sotrovimab EUA After Studies Show the Antibody Isn’t Effective Against New Omicron Variant
FDA Amends GSK’s/Vir’s Sotrovimab EUA After Studies Show the Antibody Isn’t Effective Against New Omicron Variant
The U.S. government is pulling GlaxoSmithKline’s and Vir Technology’s investigational monoclonal antibody for COVID-19 from certain states where cases of the new subvariant of Omicron, BA.2, are high, as tests have shown that the treatment isn’t effective against the new strain. And the FDA has amended sotrovimab’s Emergency Use Authorization (EUA) accordingly.